Recombinant NDV antigen and uses thereof
The present invention encompasses NDV vaccines. The vaccine may be a subunit vaccine based on HN of NDV. The NDV HN may be expressed in plants or algae including microalgae. The invention also encompasses recombinant vectors encoding and expressing NDV antigens, epitopes or immunogens which can be used to protect animals against NDV. It encompasses also a vaccination regime compatible with the DIVA strategy, including a prime-boost scheme using viral vector or inactivated vaccines and subunit vaccines.
1. A subunit vaccine comprising a recombinant Newcastle Disease Virus (NDV) Hemagglutinin-Neuraminidase (HN) antigenic polypeptide purified from microalgae and a pharmaceutically or veterinarily acceptable adjuvant, wherein the NDV HN antigenic polypeptide (i) has the sequence as set forth in SEQ ID NO: 3 and (ii) was expressed and glycosylated in the microalgae, wherein the pharmaceutically or veterinarily acceptable adjuvant is a water-in-oil emulsion, and wherein the subunit vaccine does not have other NDV polypeptides or antigens.
2. The subunit vaccine of claim 1 , wherein the NDV HN antigenic polypeptide is partially purified.
3. The subunit vaccine of claim 1 , wherein the NDV HN antigenic polypeptide is substantially purified.
4. The subunit vaccine of claim 1 , wherein the NDV HN antigenic polypeptide was encoded by a polynucleotide having the sequence as set forth in SEQ ID NO: 1 or 2.
5. A method of vaccinating an animal susceptible to NDV comprising administering to the animal the subunit vaccine according to claim 1 .
6. A method of vaccinating an animal susceptible to NDV according to a prime-boost regimen comprising: administering to the animal a prime-vaccine, and then administering to the animal a boost-vaccine, wherein at least one of the prime-vaccine and the boost-vaccine is the subunit vaccine according to claim 1 .
7. The method of claim 6 , wherein the prime-vaccine is the subunit vaccine according to claim 1 , wherein the boost-vaccine comprises a recombinant viral vector in a pharmaceutically or veterinary acceptable vehicle or excipient, wherein the recombinant viral vector contains a polynucleotide that expresses, in vivo, a NDV HN polypeptide, variant, or fragment thereof, and wherein the method protects the animal from NDV infection and/or prevents disease progression in the animal.
8. The method of claim 6 , wherein the prime-vaccine comprises a recombinant viral vector in a pharmaceutically or veterinary acceptable vehicle or excipient, wherein the recombinant viral vector contains a polynucleotide that expresses, in vivo, a NDV HN polypeptide, a variant, or fragment thereof, wherein the boost-vaccine is the subunit vaccine according to claim 1 , and wherein the method protects the animal from NDV infection and/or prevents disease progression in the animal.
9. The method of claim 6 , wherein the prime-vaccine is the subunit vaccine according to claim 1 , and wherein the boost-vaccine comprises inactivated NDV, an NDV antigen, or a combination thereof.
10. The method of claim 6 , wherein the prime-vaccine comprises inactivated NDV, an NDV antigen, or a combination thereof, and wherein the boost-vaccine is the subunit vaccine according to claim 1 .
11. The subunit vaccine of claim 1 , wherein the subunit vaccine is capable of eliciting an immune response in a host.
12. The method of claim 5 , wherein the animal is avian, equine, canine, feline, or porcine.